VCM
ACAD icon

Violich Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Violich Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$228K Hold
9,025
– – 0.02% 117
2026
Q1 		$201K Hold
9,025
– – 0.02% 118
2025
Q4 		$241K Buy
+9,025
New +$216K 0.03% 104

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Violich Capital Management's ACAD Position: Q2 2026 in Review

Violich Capital Management held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 9,025 shares worth $228K. The position accounts for 0.02% of the portfolio, ranked #117.

Violich Capital Management first reported a position in ACAD in Q4 2025 and has held it in 3 quarters since. The position peaked at $241K in Q4 2025. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Violich Capital Management held 9,025 shares of Acadia Pharmaceuticals worth $228K as of Q2 2026.
  • Violich Capital Management left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
  • Acadia Pharmaceuticals made up 0.02% of Violich Capital Management's portfolio in Q2 2026, its #117 holding.
  • Violich Capital Management first reported a position in Acadia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Violich Capital Management's Acadia Pharmaceuticals position peaked at $241K in Q4 2025.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Violich Capital Management's 13F filing for Q2 2026, filed 16 Jul 2026.